Erratum

This article refers to:

Mogamulizumab for the treatment of T-cell lymphoma

Makita S, Tobinai K. Mogamulizumab for the treatment of T-cell lymphoma. Expert Opin Biol Ther. 2017:1–9. doi: 10.1080/14712598.2017.1347634.

Available from http://dx.doi.org/10.1080/14712598.2017.1347634

When the above article was first published online, the first row entries in Table 1 were incorrectly formatted. This has been corrected in both the print and online versions and the corrected table is given below.

Table 1. Selected novel agents for relapsed/refractory T-cell lymphomas other than mogamulizumab.

Agents	Disease subtype	No of pts	ORR (%)	CR rate (%)	Median PFS	Reference
Brentuximab vedotin	ALCL	58	86	57	20 months	Pro et al. J Clin Oncol [12]
	CD30-positive PTCL	34	41	24	2.6 months	Horwitz et al. Blood [13]
	CD30-positive CTCL	64	67	16	16.7 months	Prince et al. Lancet [14]
Lenalidomide	ATL	26	42	19	3.8 months	Ishida et al. J Clin Oncol [15]
	PTCL	54	22	11	2.5 months	Morschhauser et al. Eur J Cancer [16]
Vorinostat	CTCL	74	30	NA	4.9 months	Mann et al. Clin Cancer Res [17]
Romidepsin	CTCL	71	34	5	NA	Piekarz et al. J Clin Oncol [18]
	CTCL	96	38	1	8 months	Whittaker et al. J Clin Oncol [19]
	PTCL	130	25	15	4 months	Coiffier et al. J Hematol Oncol [20]
Belinostat	PTCL	120	26	11	1.6 months	O’Connor et al. J Clin Oncol [21]
Chidamide	PTCL	79	28	14	2.1 months	Shi et al. Ann Oncol [22]
Pralatrexate	PTCL	111	29	11	3.5 months	O’Connor et al. J Clin Oncol [23]

ALCL: anaplastic large cell lymphoma; ATL: adult T-cell leukemia-lymphoma; CR: complete remission; CTCL: cutaneous T-cell lymphoma; NA: not applicable; ORR: overall response rate; PFS: progression-free survival; PTCL: peripheral T-cell lymphoma.

Taylor & Francis apologizes for this error.